No Priors: Artificial Intelligence | Technology | Startups
How AI Will Accelerate Breakthroughs in Biotechnology with Benchling CEO Sajith Wickramasekara
At this moment of inflection in technology, co-hosts Elad Gil and Sarah Guo talk to the world's leading AI engineers, researchers and founders about the biggest questions: How far away is AGI? What markets are at risk for disruption? How will commerce, culture, and society change? What’s happening in state-of-the-art in research? “No Priors” is your guide to the AI revolution. Email feedback to show@no-priors.com.
Sarah Guo is a startup investor and the founder of Conviction, an investment firm purpose-built to serve intelligent software, or "Software 3.0" companies. She spent nearly a decade incubating and investing at venture firm Greylock Partners.
Elad Gil is a serial entrepreneur and a startup investor. He was co-founder of Color Health, Mixer Labs (which was acquired by Twitter). He has invested in over 40 companies now worth $1B or more each, and is also author of the High Growth Handbook.
Show Notes
Tap timecodes to jump
Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the central system of record for biotech R&D, but uses AI agents to assist scientists to help fix this broken system. Sajith details the roadblocks that impede drug development and approval, the “dot com” bust occurring in biotech, and how AI agents and simulation can help scientists experiment faster. Plus, they talk about China’s competitive rise in the pharma space, and the unique challenges of building an interdisciplinary culture that merges the worlds of science and software.
Rebuild biotech for the AI era - Sajith Wickramasekara
Sign up for new podcasts every week. Email feedback to show@no-priors.com
Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @sajithw | @benchling
Chapters:
– Sajith Wickramasekara Introduction
– Origin and Mission of Benchling
– The Drug Development Process
– Current State of the Biotech industry
– AI’s Role in Biotech
– Benchling AI and Its Impact
– The Future of AI in Biotech
– Debunking AI Drug Discovery Myths
– Data’s Role in Biotech
– The Importance of Tools in Pharma
– AI’s Impact on Scientific Research
– Building a Biotech Company
– Interdisciplinary Collaboration in Biotech
– Tech and Biotech: Learning from Each Other
– Conclusion
Transcript not yet processed.
Sign in to unlock (1 credit)
Free to start
Full transcripts, AI insights,
Full transcripts, AI insights,
episode chat — free.
Sign up with Google in one click. 10 unlock credits included. No card needed.
Google sign-in · No credit card · Cancel anytime